论文部分内容阅读
Recombinant human erythropoietin(rhEPO)is safe and effective in treating can cer-related anemia and solid tumors in children through promoting recovery of hemat opoietic function of bone marrow and replacing renal endogenous EPO.rhE PO can significantly elevate serum Hb levle and reduce transfusion dependancy in anemiac patients.Some stu dies showed rhEPO is especially effe ctive for lymphoma and myeloma patients with lower concentration o f serum EPO.EPO levle after treatmen t and dissolubilitive transferrin r eceptor 2weeks after treatment are i n-dexes for effectiveness of rhEPO.
Recombinant human erythropoietin (rhEPO) is safe and effective in treating can cer-related anemia and solid tumors in children through promoting recovery of hemat opoietic function of bone marrow and replacing renal endogenous EPO. RhE PO can significantly elevate serum Hb levle and reduce transfusion dependancy in anemiac patients. Home stu dies showed rhEPO is more effe ctive for lymphoma and myeloma patients with lower concentration of serum EPO. EPO levle after treatmen t and dissolubilitive transferrin r eceptor 2 weeks later treatment are i ndexes for effectiveness of rhEPO.